This nonrandomized, noncontrolled clinical trial evaluates the 6-month progression-free survival, tumor objective response, and overall survival rates in patients with gastrointestinal stromal tumors treated with dasatinib.
https://ift.tt/2FhgVXy
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου